entertainment -WSS

entertainment

author：leisure time 2025-10-04 11:37:49 Page View：17697

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Doctors in states that ban abortion can still help patients
Next article： New air purifier tech could be key to improving indoor air quality

focus

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Many immigrants are left out of maternal health programs

AdobeIntheU.S.,about16% ofBlackbirthingpeopleareimmigrants.Butevenasthefederalgovernmentandstatestak

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

File-SudaneserefugeeswhofledtheconflictinSudangatherMonday,July10,2023,attheZaboutrefugeeCampinGozBe